|
Original Article
| ||||||
| Combined EZH2 and p-STAT3 protein expressions in renal cell carcinoma and their significances | ||||||
| Ola A. Harb1, Ola A. Megahed1, Rham Z. Ahmed2, Ahmed A. E. Obaya3 | ||||||
|
1Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt 3Department of Clinical oncology and Nuclear medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article] [Similar article in Pumed] [Similar article in Google Scholar] |
| How to cite this article |
| Harb OA, Megahed OA, Ahmed RZ, Obaya AAE. Combined EZH2 and p-STAT3 protein expressions in renal cell carcinoma and their significances. Edorium J Pathol 2017;4:13–24. |
|
Abstract
|
|
Aims:
It is important to detect prognostic markers for effective management of renal cell carcinoma (RCC) patients. Enhancer of zeste-homolog-2 (EZH2) and signal-transducer and activator of transcription 3 (STAT3) are a members of transcription factors which had an essential role in carcinogenesis. Our aim was to assess EZH2 and p-STAT3 as tissue protein markers expressions in RCC patients, exploring their significance in disease progression and patient survival.
Methods: In our prospective cohort study, we evaluated EZH2 and p-STAT3 tissue protein expressions using immunohistochemistry in 60 paraffin blocks of RCC, followed our patients for five years, analyzed correlations between the levels of markers expressions, clinicopthological parameters, disease progression and patients survival rates. Results: EZH2 high expression was positively correlated with higher grade (p < 0.001), advanced AJCC stage (p = 0.004), lymph node metastases (p = 0.002) and cancer progression (p < 0.001). p-STAT3 high expression was significantly positively correlated with tumor grade, AJCC stage, lymph node (p < 0.001) and distant metastases (p = 0.004 and cancer progression (p < 0.001). Survival rates were shorter in patients with high EZH and p-STAT3 expressions than cases with low expressions. Expression of both EZH and p-STAT3 was positively correlated to each other (p < 0.001). Conclusion: EZH2 and The p-STAT3 are markers of poor prognosis and can be used as therapeutic targets in RCC patients. | |
|
Keywords:
Renal cell carcinoma (RCC), EZH2 and p-STAT3, Immunohistochemistry
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions:
Ola A. Harb – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Ola A. Megahed – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Rham Z. Ahmed – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Ahmed A.E. Obaya – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© 2017 Ola A. Harb et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
ABOUT THE AUTHORS
| |||
| |||
| |||
| |||
|
